House committee substitute makes the following changes to the 2nd edition. Renumbers the proposed statute as GS 58-3-282. Makes the statute applicable to every health benefit plan offered by an insurer (was, every policy or contract of accident or health insurance and every preferred provider benefit plan) that provides coverage for prescribed, orally administered anticancer drugs that are used to kill or slow the growth of cancerous cells and that provides coverage for intravenously administered or injected anticancer drugs. Deletes the provision that stated nothing in the statute applies to accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, disability income, or other limited benefit health insurance policies.

Changes the effective date of the act from January 1, 2014, to January 1, 2015. Adds that the act does not become effective if the act is determined by the federal government to create a state-required benefit that is in excess of the essential health benefits pursuant to 45 CFR 155.170(a)(3).